tetano
Editor, Senior Moderator
BMC Med
. 2024 Sep 4;22(1):360.
doi: 10.1186/s12916-024-03589-4. New-onset obstructive airway disease following COVID-19: a multicenter retrospective cohort study
Min-Hsiang Chuang[SUP] 1 [/SUP], Wei Hsu[SUP] 2 [/SUP], Ya-Wen Tsai[SUP] 3 4 [/SUP], Wan-Hsuan Hsu[SUP] 2 [/SUP], Jheng-Yan Wu[SUP] 5 [/SUP], Ting-Hui Liu[SUP] 6 [/SUP], Po-Yu Huang[SUP] 2 [/SUP], Chih-Cheng Lai[SUP] 7 8 [/SUP]
Affiliations
Background: The study assessed the association between COVID-19 and new-onset obstructive airway diseases, including asthma, chronic obstructive pulmonary disease, and bronchiectasis among vaccinated individuals recovering from COVID-19 during the Omicron wave.
Methods: This multicenter retrospective cohort study comprised 549,606 individuals from the U.S. Collaborative Network of TriNetX database, from January 8, 2022, to January 17, 2024. The hazard of new-onset obstructive airway diseases between COVID-19 and no-COVID-19 groups were compared following propensity score matching using the Kaplan-Meier method and Cox proportional hazards model.
Results: After propensity score matching, each group contained 274,803 participants. Patients with COVID-19 exhibited a higher risk of developing new-onset asthma than that of individuals without COVID-19 (adjusted hazard ratio (aHR), 1.27; 95% CI, 1.22-1.33; p < 0.001). Stratified analyses by age, SARS-CoV-2 variant, vaccination status, and infection status consistently supported this association. Non-hospitalized individuals with COVID-19 demonstrated a higher risk of new-onset asthma (aHR, 1.27; 95% CI, 1.22-1.33; p < 0.001); however, no significant differences were observed in hospitalized and critically ill groups. The study also identified an increased risk of subsequent bronchiectasis following COVID-19 (aHR, 1.30; 95% CI, 1.13-1.50; p < 0.001). In contrast, there was no significant difference in the hazard of chronic obstructive pulmonary disease between the groups (aHR, 1.00; 95% CI, 0.95-1.06; p = 0.994).
Conclusion: This study offers convincing evidence of the association between COVID-19 and the subsequent onset of asthma and bronchiectasis. It underscores the need for a multidisciplinary approach to post-COVID-19 care, with a particular focus on respiratory health.
Keywords: Asthma; Bronchiectasis; COPD; COVID-19; Obstructive airway diseases.
. 2024 Sep 4;22(1):360.
doi: 10.1186/s12916-024-03589-4. New-onset obstructive airway disease following COVID-19: a multicenter retrospective cohort study
Min-Hsiang Chuang[SUP] 1 [/SUP], Wei Hsu[SUP] 2 [/SUP], Ya-Wen Tsai[SUP] 3 4 [/SUP], Wan-Hsuan Hsu[SUP] 2 [/SUP], Jheng-Yan Wu[SUP] 5 [/SUP], Ting-Hui Liu[SUP] 6 [/SUP], Po-Yu Huang[SUP] 2 [/SUP], Chih-Cheng Lai[SUP] 7 8 [/SUP]
Affiliations
- PMID: 39227934
- PMCID: PMC11373398
- DOI: 10.1186/s12916-024-03589-4
Background: The study assessed the association between COVID-19 and new-onset obstructive airway diseases, including asthma, chronic obstructive pulmonary disease, and bronchiectasis among vaccinated individuals recovering from COVID-19 during the Omicron wave.
Methods: This multicenter retrospective cohort study comprised 549,606 individuals from the U.S. Collaborative Network of TriNetX database, from January 8, 2022, to January 17, 2024. The hazard of new-onset obstructive airway diseases between COVID-19 and no-COVID-19 groups were compared following propensity score matching using the Kaplan-Meier method and Cox proportional hazards model.
Results: After propensity score matching, each group contained 274,803 participants. Patients with COVID-19 exhibited a higher risk of developing new-onset asthma than that of individuals without COVID-19 (adjusted hazard ratio (aHR), 1.27; 95% CI, 1.22-1.33; p < 0.001). Stratified analyses by age, SARS-CoV-2 variant, vaccination status, and infection status consistently supported this association. Non-hospitalized individuals with COVID-19 demonstrated a higher risk of new-onset asthma (aHR, 1.27; 95% CI, 1.22-1.33; p < 0.001); however, no significant differences were observed in hospitalized and critically ill groups. The study also identified an increased risk of subsequent bronchiectasis following COVID-19 (aHR, 1.30; 95% CI, 1.13-1.50; p < 0.001). In contrast, there was no significant difference in the hazard of chronic obstructive pulmonary disease between the groups (aHR, 1.00; 95% CI, 0.95-1.06; p = 0.994).
Conclusion: This study offers convincing evidence of the association between COVID-19 and the subsequent onset of asthma and bronchiectasis. It underscores the need for a multidisciplinary approach to post-COVID-19 care, with a particular focus on respiratory health.
Keywords: Asthma; Bronchiectasis; COPD; COVID-19; Obstructive airway diseases.